RT Journal Article
T1 Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study.
A1 Yubero-Serrano, Elena M
A1 Alcala-Diaz, Juan F
A1 Gutierrez-Mariscal, Francisco M
A1 Arenas-de Larriva, Antonio P
A1 Peña-Orihuela, Patricia J
A1 Blanco-Rojo, Ruth
A1 Martinez-Botas, Javier
A1 Torres-Peña, Jose D
A1 Perez-Martinez, Pablo
A1 Ordovas, Jose M
A1 Delgado-Lista, Javier
A1 Gomez-Coronado, Diego
A1 Lopez-Miranda, Jose
K1 Cholesterol efflux capacity
K1 Coronary heart disease
K1 Peripheral artery disease
K1 Secondary prevention
K1 Type 2 diabetes mellitus
AB Peripheral artery disease (PAD) is recognized as a significant predictor of mortality and adverse cardiovascular outcomes in patients with coronary heart disease (CHD). In fact, coexisting PAD and CHD is strongly associated with a greater coronary event recurrence compared with either one of them alone. High-density lipoprotein (HDL)-mediated cholesterol efflux capacity (CEC) is found to be inversely associated with an increased risk of incident CHD. However, this association is not established in patients with PAD in the context of secondary prevention. In this sense, our main aim was to evaluate the association between CEC and PAD in patients with CHD and whether the concurrent presence of PAD and T2DM influences this association. CHD patients (n = 1002) from the CORDIOPREV study were classified according to the presence or absence of PAD (ankle-brachial index, ABI ≤ 0.9 and ABI > 0.9 and  0.9 and  The presence of PAD determined low CEC in non-T2DM and newly-diagnosed T2DM patients. Coexisting PAD and newly-diagnosed T2DM provided and additive effect providing an impaired CEC compared to non-T2DM patients with PAD. In established T2DM patients, the presence of PAD did not determine differences in CEC, compared to those without PAD, which may be restored by glucose-lowering treatment. Our findings suggest an inverse relationship between CEC and PAD in CHD patients. These results support the importance of identifying underlying mechanisms of PAD, in the context of secondary prevention, that provide potential therapeutic targets, that is the case of CEC, and establishing strategies to prevent or reduce the high risk of cardiovascular events of these patients.
PB BioMed Central
YR 2021
FD 2021-03-13
LK http://hdl.handle.net/10668/17403
UL http://hdl.handle.net/10668/17403
LA en
NO Yubero-Serrano EM, Alcalá-Diaz JF, Gutierrez-Mariscal FM, Arenas-de Larriva AP, Peña-Orihuela PJ, Blanco-Rojo R, et al. Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study. Cardiovasc Diabetol. 2021 Mar 25;20(1):72. doi: 10.1186/s12933-021-01260-3. Erratum in: Cardiovasc Diabetol. 2021 Apr 17;20(1):79
DS RISalud
RD Apr 6, 2025